Program
Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387
Its studies are mostly in Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Dec 12, 20231 company-led study, 1 open or runningNext primary completion: Mar 16, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | Mar 16, 2027phase 1 · NCT06178614 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-0387
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06178614 · 200 planned · United States, France, Spain
Ahead
- Mar 16, 2027Primary completion: phase 1 study in NeoplasmsNCT06178614
TargetBeta
“A human bispecific antibody directed against both ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3; NPP3; B10; PDNP3; CD203c; PD-IBETA) and the T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-ENPP3/anti-C…”NCIt, read by Claude
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06178614Neoplasms · United States, France, Spain | 1 | Recruiting | Mar 16, 2027 | 200 |
How it is read
Names in the registry
- “JNJ-87890387”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.